Meeder Asset Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Meeder Asset Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,578	Closed	-$27K	–	2498
2021 Q3	$27K	Buy	3,578 +371	+12%	+$2.3K	﹤0.01%	1322
2021 Q2	$22K	Sell	3,207 -366	-10%	-$3.04K	﹤0.01%	1436
2021 Q1	$37K	Buy	+3,573	New	+$39.1K	﹤0.01%	1201
2020 Q4	–	Sell	-3,451	Closed	-$29K	–	2332
2020 Q3	$29K	Sell	3,451 -582	-14%	-$3.61K	﹤0.01%	1073
2020 Q2	$28K	Buy	4,033 +3,077	+322%	+$16.6K	﹤0.01%	1058
2020 Q1	$5K	Sell	956 -11,194	-92%	-$64.4K	﹤0.01%	1829
2019 Q4	$106K	Sell	12,150 -7,989	-40%	-$43.2K	0.01%	776
2019 Q3	$68K	Buy	20,139 +15,105	+300%	+$60.5K	﹤0.01%	916
2019 Q2	$25K	Buy	5,034 +3,594	+250%	+$19.1K	﹤0.01%	1163
2019 Q1	$9K	Sell	1,440 -1,380	-49%	-$6.67K	﹤0.01%	1282
2018 Q4	$9K	Buy	2,820 +786	+39%	+$3.67K	﹤0.01%	1287
2018 Q3	$13K	Buy	2,034 +1,833	+912%	+$13.6K	﹤0.01%	1117
2018 Q2	$1.54K	Sell	201 -62	-24%	-$894	﹤0.01%	1449
2018 Q1	$6K	Buy	+263	New	+$5.84K	﹤0.01%	1195
2017 Q4	–	Sell	-490	Closed	-$8K	–	1841
2017 Q3	$8K	Buy	+490	New	+$6.93K	﹤0.01%	1141

Other funds holding JNCE

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Meeder Asset Management's JNCE Position: Q4 2021 in Review

Meeder Asset Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2021, closing a stake of 3,578 shares — an estimated $27K sold.

Meeder Asset Management first reported a position in JNCE in Q3 2017 and held it in 15 quarters. The position peaked at $106K in Q4 2019. 124 funds tracked by Wall St. Rank hold JNCE as of Q4 2021.

Meeder Asset Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Meeder Asset Management sold 3,578 Jounce Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $27K.
Meeder Asset Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2017 and held it in 15 quarters.
Meeder Asset Management's Jounce Therapeutics, Inc. Common Stock position peaked at $106K in Q4 2019.
124 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Meeder Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.